Furthermore, anti-CD3 can reduce the titers of pre-existing anti-FVIII inhibitory antibodies in hemophilia A mice.
ABSTRACT
Furthermore, anti-CD3 can reduce the titers of pre-existing anti-FVIII inhibitory antibodies in hemophilia A mice.
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INTRODUCTION
Gene therapy protocols using viral and nonviral vectors have been devised for many diseases and employed in preclinical studies. Recent studies indicate that immune responses against vectors or transgene products can become major obstacles for successful application of gene therapy [1] [2] [3] . Hemophilia A, a congenital bleeding disorder caused by a monogenic defect of coagulation factor VIII (FVIII), is an ideal candidate for the successful application of Therapeutic biological compounds have been used successfully to modulate the immune system. The development of the first humanized anti-CD3 monoclonal antibody (OKT3) spurred a spate of studies with CD3-specific antibodies for the treatment of immune-mediated diseases [10] [11] [12] [13] [14] [15] . Clinical trials with this monoclonal antibody included treatment of acute renal allograft rejection 16, 17 , autoimmune insulin-dependent diabetes 18 , and psoriatic arthritis 19 , and prevention of islet allograft rejection 20 . The results of these trials are encouraging and anti-CD3 treatment did not elicit major side effects 16, 17 . Anti-CD3 therapy was demonstrated to promote, in both transplantation 21, 22 and autoimmune settings 23 , antigen-specific immune tolerance. In patients with recent onset autoimmune diabetes, reversion of hyperglycemia was achieved by combination therapy of anti-CD3
injections and intranasal application of proinsulin peptide, but not by either agent alone 23 .
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Experimental evidence supports the hypothesis that there are two subsets of Tregs which differ in specificity and effector mechanism 24 . Natural Tregs emerge from the thymus as a distinct lineage, whereas adaptive Tregs are induced at the periphery from CD4 + CD25 -T cells under specific conditions, i.e. antigenic stimulation in the presence of a particular cytokine environment or altered TCR signal transduction. Studies in mice engineered to express a Foxp3 reporter confirmed that Foxp3 is a lineage marker of Tregs and correlates with suppressor activity irrespective of CD25 expression [25] [26] [27] . 
MATERIALS AND METHODS
Mice. All mice were kept in accordance with National Institutes of Health guidelines for animal care and the guideline of Seattle Children's Research Institute, and maintained at a specific pathogen-free facility. The animal protocols used in this study were approved by the institutional IACUC Committee of Seattle Children's Research Institute.
Hemophilia A mice in a 129/SV × C57BL/6 mixed genetic background were generated by targeted disruption of exon 16 of the FVIII gene 29 and bred in our animal facility.
Antibodies. Anti-mouse-CD3ε monoclonal antibodies (145-2C11), anti-mouse-CD25 monoclonal antibodies (PC61), and mouse IgG1 isotype control were purchased from Assays for measuring FVIII activities and anti-FVIII inhibitory antibodies. FVIII activity was measured by a modified clotting assay using reagents to measure activated partial thromboplastin time (APTT) and FVIII deficient plasma 9, 30 . FVIII activity was calculated from a standard curve generated by using serially diluted normal human pooled plasma.
Inhibitory antibodies against FVIII were measured by Bethesda assay as previously described 31 . hFVIII specific antibodies (total IgGs) were assessed by ELISA using the same method described previously 9 . Sera collected 2 weeks before and after second FVIII plasmid challenge were used. Serum samples were analyzed for phage-neutralizing antibody activity and expressed as the rate of phage inactivation (Kv) using the standard formula 33 : Kv = (dilution of serum/time of phage-serum incubation in minutes) x ln (phage assay PFU at 0 minute/phage assay PFU at 60 minutes). Antibody resistant to 2 mercaptoethanol (2-ME) was considered to be of the IgG isotype.
Statistics.
Data are expressed as mean ± S.D. The statistical significance of the difference between means was determined using the 2-tailed Student's t test. Differences were considered significant at P<0.05.
RESULTS

Anti-CD3 induces tolerance to FVIII after FVIII plasmid-mediated gene therapy
To test if CD3-specific antibody can modulate transgene-specific immune responses following FVIII plasmid-mediated gene therapy, we injected hemophilia A mice (n=13/group) with 50 µg FVIII plasmid by hydrodynamic injection (day 0) and gave five daily infusions of anti-CD3ε at a dose of 40µg/day (days 0-4) via tail vein. Plasma samples were collected from treated and naïve mice at scheduled time points and FVIII activities and inhibitory antibody titers were assessed.
As we have previously shown 34, 35 , injection of FVIII plasmid alone produced shortterm high-levels of FVIII activity in hemophilia A mice, followed by a gradual decrease to undetectable levels in 2-4 weeks due to the development of anti-FVIII inhibitory antibodies ( Fig. 1a&b ). In contrast, immuno-modulation with anti-CD3 led to persistently therapeutic levels of FVIII activities (30-105% of FVIII levels in normal human plasma) for up to 24 weeks in 11 out of the 13 FVIII plasmid treated mice ( Fig.   1c ). For the remaining two anti-CD3 treated mice, FVIII activities persisted at therapeutic levels for 10 and 15 weeks, respectively, before dropping to undetectable levels (Fig 1c) .
Most importantly, none of the 13 treated mice developed FVIII inhibitory antibodies throughout the 24 weeks experimental period (Fig. 1d) . In addition, when we treated mice using a lower dosage of anti-CD3 (5µg/day at days 0-4, n=4/group), none of the mice developed antibody response up to 12 weeks past plasmid injection, indicating that this lower dosage was also able to induce tolerance to FVIII in hemophilia A mice.
To assess transgene-specific T cell proliferation, we isolated splenic CD4 + T cells from naïve, anti-CD3 only, FVIII plasmid only and FVIII plasmid+anti-CD3 treated mice Mice with persistent FVIII expression after the 1 st FVIII plasmid injection continued to generate detectable FVIII expression after the 2 nd challenge (Fig. 3a) . In contrast, the mouse with undetectable FVIII expression 12 weeks after the 1 st treatment only boosted FVIII expression for a couple of weeks following the 2 nd plasmid challenge then became again undetectable (Fig. 3a) . None of the anti-CD3 treated mice developed detectable Table 1 ). However, we detected low levels of nonneutralizing antibodies (~70ng/ml) in FVIII plasmid + anti-CD3 mice of short-term FVIII expression at 2 weeks before and after 2 nd plasmid injection (Supplement Table 1 only and FVIII plasmid+anti-CD3 treated mice but not in plasmid only treated animals ( Fig. 4a and 4d) . A detailed flow cytometric analysis of peripheral blood lymphocytes showed that the levels of CD4 + T cells declined most significantly at week 1 and gradually returned to normal within 8 weeks in both anti-CD3 only and FVIII plasmid+anti-CD3 treated groups (Fig. 4d) . FVIII plasmid injection had no effect on anti-CD3 induced CD4 + T cell depletion.
Anti-CD3 treatment resulted in significantly higher percentage of CD4 + Foxp3 + T cells in spleen (Fig. 4a) , lymph node (supplement Fig. 1 (Fig. 4C ) and lymph nodes (Supplement Fig. 1 Fig. 4c and supplement Fig. 1) . At 4 and 6 weeks after plasmid injection, the distribution of CD25 + and CD25 -cells in CD4 + Foxp3 + T cells in spleens of FVIII plasmid+anti-CD3 mice gradually returned to levels comparable to that in spleens of naïve mice and FVIII plasmid only treated mice (Fig. 4c) .
A recent study suggested that CD3 specific antibody increases the level of transforming growth factor-β1 (TGF-β1) in vivo, leading to the generation of CD4 + CD25 + Foxp3 + regulatory T cells and tolerance 36 . We investigated the TGF-β1 levels in the plasma of naïve and FVIII plasmid+anti-CD3 treated mice. Two FVIII plasmid+anti-CD3 tolerized mice (mouse #4 and #5, Table 2 ) had increased TGF-β1 levels at day 3 and/or day 10 after the last anti-CD3 injection, compared to that of naive mice (mouse #1, #2, and #3). Mouse #6 which lost FVIII activity at about 12 weeks did not produce higher plasma TGF-β 1 at day 3 and/or day 10. (Fig. 5a ). However, when we used CD4 + CD25 + Treg cells isolated from
mice six weeks or more after FVIII plasmid injection, we observed FVIIIspecific suppression (Fig. 5b) . To deplete CD4 + CD25 + Tregs, we treated hemophilia A mice with anti-CD25
(clone: PC61) monoclonal antibodies prior to FVIII plasmid and anti-CD3 injection as outlined in Fig. 5a . Injection of 1mg anti-CD25 at day 0 plus a second injection of 0.5mg
anti-CD25 at day 14 ( Fig. 6a) None of the mice developed inhibitory antibodies during the time of study (data not shown). These results are in agreement with a previous report 14 , suggesting that prior treatment with anti-CD25 does not abrogate anti-CD3 induced tolerance.
Un-related T-dependent and T-independent antigen challenge
Since anti-CD3 treatment temporarily depleted a large portion of the T cell compartment, the long term effect on the immune system was investigated. Two FVIII plasmid+anti-CD3 tolerized mice and two control naïve mice were inoculated with the Tdependent antigen, bacteriophage Ф x174 33 , and another two groups with the Tindependent antigen, TNP-ficoll 24 weeks after plasmid delivery. Peak antibody titers observed at 2 weeks post primary and 1 week post secondary Ф x174 immunization and isotype switching (percent phage specific IgG) during secondary immunization were not different between the 2 groups (Fig. 7a) . As shown in Fig. 7 , no significant difference in serum levels of anti-TNP IgG3 (Fig. 7b) or anti-TNP IgM (Fig. 7c) were found between tolerized mice and FVIII plasmid only treated mice. Together, these data indicated that
transient immunomodulation with anti-CD3 does not adversely affect immune responses to T-dependent or T-independent neoantigens.
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To date, there is no clinical or laboratory risk factors that allow the identification of a patient who will develop antibody. Therefore, it is very important to develop a strategy to treat pre-existing inhibitory antibodies. Thus, we injected a group of hemophilia A mice (n=4/group) with 50 µg FVIII plasmid by hydrodynamic injection (week -8). Eight weeks post plasmid injection, 2 mice developed high-titer anti-FVIII antibody and 2 mice developed low-titer antibody. All 4 mice were subjected to five daily infusions of anti-CD3ε at a dose of 40µg/day (days 0-4) via tail vein. Anti-FVIII antibody titers were significantly reduced or eliminated and FVIII activities recovered to detectable levels 2 weeks following anti-CD3 treatment (Table 4) . However, FVIII activities declined and anti-FVIII antibody titers re-appeared at low-titers or increased at later time points.
These data indicated that anti-CD3 can partially modulate pre-existing anti-FVIII immune responses. treatment, the absolute numbers slightly decreased. This is most likely due to the selective depletion of activated effector and naive T cells in the CD4 compartment due to higher CD3 expression in these populations (Fig. 4b) treated mice at week 6 after plasmid injection suppressed proliferation of FVIII-specific effector T cells (Fig. 6b) , (2) The CD4 + T cells transferred dominant, FVIII-specific tolerance to syngenic naive mice (Table 3) .
It has been shown that CD3 specific antibody treatment promotes the production of systemic transforming growth factor-β1 (TGF-β1), which is known to induce transplantation and autoimmune models. The dosage and schedule used in our study are comparable to those used in human trials 14, 15, 18, 23 . Anti-CD3 immunomodulation has the potential to be a safe and effective strategy to prevent FVIII-specific immune responses following gene therapy or protein replacement therapy. Our data also indicates that anti-CD3 can reduce the titers of pre-existing inhibitors and will be an excellent candidate in a combination therapy for modulating anti-FVIII immune responses in hemophilia mice with established inhibitors. 
